Please assess the completion status of the following clinical trial:

Trial Title: Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed, unresectable locally advanced (stage IIIB with pleural effusion) and/or metastatic (stage IV) NSCLC~* Progression to first-line therapy for advanced/metastatic NSCLC~* Bi-dimensionally measurable disease (not included in radiation field)~* ECOG performance status of 0-2~* Life expectancy of more than 6 months~* Adequate liver (serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases,adequate renal function (serum creatinine \<1.5 times the upper normal limit),and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function~* Signed informed consent~Exclusion Criteria:~* Central nervous system involvement (unless if the patient has being previously irradiated and is clinically stable)~* Presence of a centrally located mass or a tumor mass in close relation to large vessels or a mass with cavitation.~* Surgery or radiation therapy within the last 14 days from study entry~* Active infection~* History of life-threatening hemoptysis / hematemesis, history of thrombosis or use of anti-coagulation therapy~* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction, ventricular arrhythmias) or stroke within the previous 6 months or uncontrolled hypertension~* Patients on other experimental treatment protocols~* History of a second primary malignancy (other than basal-cell skin carcinoma or in situ carcinoma of the cervix)~* Psychiatric illness or social situation that would preclude study compliance~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Erlotinib/Bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).